

# Minneapolis Heart Institute Foundation Cardiovascular Grand Rounds

CloudCME ID: 1239

Text ID to: 844-939-3950 (your email must be paired)

**DATE:** January 26, 2026

**TIME:** 7:00 AM - 8:00 AM

**LOCATION:**

MHI Building - MHIF Suite 100  
Learning Center - Virtual Zoom

**TOPIC(S) OR TITLE:** Discovery of VEXAS Syndrome

**FACULTY:**

**Peter Grayson, MD, MSc**

Senior Investigator, NIH

Acting Program Director, NIAMS Rheumatology Training Program

## OVERVIEW/PURPOSE STATEMENT:

Our Cardiovascular Grand Rounds offers physicians and other health care providers the opportunity to review and discuss the latest developments in cardiovascular care every Monday morning during our Grand Rounds seasons. These weekly meetings feature topics across the spectrum of cardiovascular medicine. Practitioners share research highlights, offer treatment or diagnostic best practices, and collaborate to improve care for those with cardiovascular disease.

## OVERALL OBJECTIVES:

1. Demonstrate improved awareness of emerging cardiovascular clinical care standards derived from new research
2. Discuss the implications of new cardiovascular care guidelines and develop more standardized approaches to treating cardiovascular disease
3. Utilize current evidence based guidelines to improve standards of care for individuals with cardiovascular diseases

Location: MHI Building - MHIF Suite 100 Learning Center - Virtual Zoom

Specialties: Cardiovascular Disease

## LECTURE-SPECIFIC OBJECTIVES:

1. Recognize the clinical features of VEXAS syndrome
2. Understand the pathogenetics of VEXAS syndrome
3. Review the role of somatic mutations in non-malignant diseases

# Regularly Scheduled Series

## Continuing Medical Education (CME)



### DISCLOSURE POLICY AND STATEMENTS:

Allina Health, Office of Accreditation intends to provide balance, independence, objectivity, and scientific rigor in all of its educational activities and will adhere to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. The ACCME defines an ineligible company as "any entity" whose primary business is producing, marketing, re-selling, or distributing health care products/services used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

Any individual in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests) that have existed WITHIN THE LAST 24 MONTHS, even if it has now ended. All relevant financial relationships/conflicts of interest have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Ross Garberich, MS, MBA	Other Planning Committee Member	Nothing to disclose - 11/18/2025
Peter Grayson, MD	Faculty	Nothing to disclose - 01/19/2026
David Hurrell, MD	Lead Physician	Consulting Fee-Boston Scientific Corporation - 11/21/2025
Cindy Resman, Other	Other Planning Committee Member	Nothing to disclose - 11/20/2025
Scott Sharkey, MD	Other Planning Committee Member	Consulting Fee-Medtronic (Any division) - 11/20/2025